SHISAL2B: A Potential Drug Target and Biomarker (G100132916)
SHISAL2B: A Potential Drug Target and Biomarker
Shisal2b, also known as SHISAL-2B, is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. Its full name is SHISAL2B gene family, and it is part of the superfamily of RNA-binding proteins (RBP). SHISAL2B has been identified as a potential drug target and biomarker for several diseases, including neurodegenerative disorders, autoimmune diseases, and cancer.
The SHISAL2B gene
The SHISAL2B gene is located on chromosome 12q34 and has a length of 1,343 amino acids. It is characterized by a unique open reading frame (ORF) that includes a 5'-end region, a 3'-end region, and a middle regions that contain multiple functional domains, including a leucine-rich repeat (LRR), a calbindin domain, and a G-CSC domain.
The SHISAL2B protein
SHISAL2B is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is primarily localized to the nuclei and mitochondria of the cells, and it is also detectable in the cytoplasm of the cells. SHISAL2B is a protein that can interact with other proteins, including histone-modifying enzymes, non-coding RNAs (ncRNAs), and proteins involved in stress responses.
The SHISAL2B gene is involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. It is well-known for its role in the regulation of cell proliferation and has been implicated in the development and progression of various diseases, including neurodegenerative disorders, autoimmune diseases, and cancer.
Potential drug targets
SHISAL2B has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. Several studies have suggested that SHISAL2B may be a useful target for drugs that are designed to modulate its activity, including small molecules, antibodies, and vaccines.
One potential mechanism by which SHISAL2B may be targeted is by drugs that interfere with its ability to interact with other proteins. For example, small molecules that bind to SHISAL2B's LRR and G-CSC domains have been shown to inhibit its activity. Similarly, antibodies that recognize and target SHISAL2B have been shown to be effective in blocking its activity.
Another potential mechanism by which SHISAL2B may be targeted is by drugs that disrupt its ability to regulate cell proliferation. For example, inhibitors of SHISAL2B's activity have been shown to disrupt its ability to promote cell proliferation and to induce cell apoptosis.
Biomarker potential
SHISAL2B has also been identified as a potential biomarker for several diseases, including neurodegenerative disorders, autoimmune diseases, and cancer. Its expression has been observed in various tissues of the human body, including the brain, heart, and kidneys, and its levels have been associated with the development and progression of these diseases.
For example, SHISAL2B has been shown to be expressed in the brains of individuals with Alzheimer's disease, and its levels have been linked to the severity of the disease. Similarly, SHISAL2B has been shown to be expressed in the tissues of individuals with multiple sclerosis, a progressive autoimmune disease, and its levels have been associated with the severity of the disease.
Conclusion
In conclusion, SHISAL2B is a protein that has been identified as a potential drug target and biomarker for several diseases. Its unique structure and its involvement in various cellular processes make it an attractive target for small molecules, antibodies, and vaccines. Further research is needed to fully understand its potential as a drug and to develop effective treatments for the diseases associated with its expression.
Protein Name: Shisa Like 2B
More Common Targets
SHKBP1 | SHLD1 | SHLD2 | SHLD2P1 | SHLD2P3 | SHLD3 | SHMT1 | SHMT2 | SHOC1 | SHOC2 | Short transient receptor potential channel (TrpC) | SHOX | SHOX2 | SHPK | SHPRH | SHQ1 | SHROOM1 | SHROOM2 | SHROOM3 | SHROOM4 | SHTN1 | SI | SIAE | SIAH1 | SIAH2 | SIAH3 | Sialidase | Sialyltransferase | SIDT1 | SIDT2 | SIGIRR | SIGLEC1 | SIGLEC10 | SIGLEC11 | SIGLEC12 | SIGLEC14 | SIGLEC15 | SIGLEC16 | SIGLEC17P | SIGLEC5 | SIGLEC6 | SIGLEC7 | SIGLEC8 | SIGLEC9 | SIGLECL1 | sigma Receptor | SIGMAR1 | Signal peptidase complex | Signal recognition particle | Signal recognition particle receptor | Signal Transducers and Activators of Transcription (STAT) | SIK1 | SIK2 | SIK3 | SIKE1 | SIL1 | SILC1 | SIM1 | SIM2 | SIMC1 | SIN3 complex | SIN3A | SIN3B | SINHCAF | SIPA1 | SIPA1L1 | SIPA1L1-AS1 | SIPA1L2 | SIPA1L3 | SIRPA | SIRPAP1 | SIRPB1 | SIRPB2 | SIRPB3P | SIRPD | SIRPG | SIRPG-AS1 | SIRT1 | SIRT2 | SIRT3 | SIRT4 | SIRT5 | SIRT6 | SIRT7 | SIT1 | SIVA1 | SIX1 | SIX2 | SIX3 | SIX3-AS1 | SIX4 | SIX5 | SIX6 | SKA1 | SKA1 complex | SKA2 | SKA2P1 | SKA3 | SKAP1 | SKAP1-AS2